a0103a
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of May 2021
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca prices
a EUR800mn bond offering
27 May 2021 07:00
BST
AstraZeneca prices a €800m bond
offering
AstraZeneca PLC ("AstraZeneca") announces that, on 26 May 2021, it
successfully priced €800m ($1bn equivalent) of fixed rate
notes with a coupon of 0.375%, maturing on 3 June 2029 (the
"Notes").
The Notes will be subject to special mandatory redemption if the
acquisition of Alexion Pharmaceuticals, Inc. ("Alexion") (the
"Alexion Acquisition") is not consummated on or before 12 March
2022 or, if prior to such date, AstraZeneca notifies the trustee
that AstraZeneca will not pursue the consummation of the Alexion
Acquisition.
AstraZeneca expects to use the net proceeds of the offering to fund
a portion of the purchase price for the Alexion Acquisition, to pay
or refinance a portion of Alexion's indebtedness and to pay related
fees and expenses, or for general corporate purposes.
The Notes will be issued under the $10,000,000,000 EMTN programme
of AstraZeneca and AstraZeneca Finance LLC, which AstraZeneca filed
with the UK Financial Conduct Authority on 24 May 2021, and
admitted to listing on the UK Financial Conduct Authority's
Official List and to trading on the London Stock Exchange's Main
Market.
The Notes have not been registered under the U.S. Securities Act of
1933 and may not be offered or sold in the United States absent
registration or an applicable exemption from
registration.
This announcement shall not constitute an offer to sell or the
solicitation of an offer to buy the Notes described herein, nor
shall there be any sale of these Notes in any jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
jurisdiction.
The issuance of the Notes does not impact AstraZeneca's financial
guidance for 2021.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines in
Oncology and BioPharmaceuticals, including Cardiovascular, Renal
& Metabolism, and Respiratory & Immunology. Based in
Cambridge, UK, AstraZeneca operates in over 100 countries, and its
innovative medicines are used by millions of patients
worldwide.
AstraZeneca contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
27 May 2021
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|